Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis
Por:
De Moner, B, Martinez-Sanchez, J, Garrote, M, Ramos, A, Ventosa-Capell, H, Moreno-Castaño, A, Nomdedeu, M, Ojeda, A, Escolar, G, Garcia-Pagan, JC, Arellano-Rodrigo, E, Carreras, E, Alvarez-Larran, A and Díaz-Ricart, M
Publicada:
1 oct 2025
Ahead of Print:
1 ene 2025
Resumen:
Background JAK2V617F-mutated myeloproliferative neoplasms (MPN) exhibit abnormal proliferation of bone marrow progenitors and increased risk of thrombosis, specifically in splanchnic veins (SVT). The contribution of the endothelium to the development of the prothrombotic phenotype was explored. Material and methods Plasma and serum samples from JAK2V617F MPN patients with (n=26) or without (n=7) thrombotic debut and different treatments, were obtained (n=33). Cultured endothelial cells (ECs) were exposed to serum samples from these patients and from healthy donors as controls. Changes in markers of inflammation (VCAM-1, ICAM-1), cell permeability (VE-cadherin), production of VWF, extracellular matrix (ECM) reactivity, and activation of intracellular signaling pathways related to stress, proliferation, inflammation (Akt, p44/42, IkBa), and JAK2/STAT3 pathway, were assessed by immunofluorescence, flow adhesion, SDS-PAGE and immunoblot. Additionally, circulating markers of endothelial activation and damage (VWF, sVCAM-1, sTNFRI, thrombomodulin, angiopoietin-2, a2-antiplasmin activity, PAI-1) were evaluated in Patients' plasma. Results The in vitro studies showed that EC exposure to MPN thrombotic patients' sera resulted in increased VCAM-1 and ICAM-1, and reduced VE-cadherin expression (p<0.05) at the cell surface. Production and release of VWF to the ECM were higher (p<0.05), with increased platelet adhesion after perfusing whole blood, being more noticeable in response to sera from non-treated patients. Furthermore, intracellular activation of Akt, p44/42, IkBa and JAK2/STAT3 was observed. Moreover, plasma levels of VWF, TNF-R1, VCAM-1, thrombomodulin, and angiopoietin-2 were higher in JAK2V617F+ MPN patients with thrombosis. Conclusion The present findings suggest that circulating factors in MPNs with SVT debut induce endothelial proinflammatory and prothrombotic phenotypes, which are modulated in vitro with MPN treatment.
Filiaciones:
:
Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Ctr Diagnost Biomed CDB,Hemostasis & Erythropathol, Barcelona, Spain
Barcelona Univ, Hosp Clin Barcelona, Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Barcelona Endothelium Team, Barcelona, Spain
Martinez-Sanchez, J:
Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Ctr Diagnost Biomed CDB,Hemostasis & Erythropathol, Barcelona, Spain
Garrote, M:
Hosp Clin Barcelona, Ctr Diagnost Biomed CDB, Pathol Dept, Hematopathol Sect,IDIBAPS, Barcelona, Spain
Ramos, A:
Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Ctr Diagnost Biomed CDB,Hemostasis & Erythropathol, Barcelona, Spain
Barcelona Endothelium Team, Barcelona, Spain
Ventosa-Capell, H:
Hosp Clin Barcelona, Med Intens Care Unit, Barcelona, Spain
Moreno-Castaño, A:
Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Ctr Diagnost Biomed CDB,Hemostasis & Erythropathol, Barcelona, Spain
Barcelona Endothelium Team, Barcelona, Spain
Nomdedeu, M:
Hosp Clin Barcelona, Inst Canc & Malalties Sang ICAMS, Hemostasis & Hemotherapy Dept, Barcelona, Spain
Ojeda, A:
Hosp Clin Barcelona, Liver Unit, Barcelona Hepat Haemodynam Lab, IDIBAPS, Barcelona, Spain
CIBERehd, Barcelona, Spain
Escolar, G:
Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Ctr Diagnost Biomed CDB,Hemostasis & Erythropathol, Barcelona, Spain
Barcelona Endothelium Team, Barcelona, Spain
Garcia-Pagan, JC:
Hosp Clin Barcelona, Liver Unit, Barcelona Hepat Haemodynam Lab, IDIBAPS, Barcelona, Spain
CIBERehd, Barcelona, Spain
Arellano-Rodrigo, E:
Hosp Clin Barcelona, Inst Canc & Malalties Sang ICAMS, Hemostasis & Hemotherapy Dept, Barcelona, Spain
Carreras, E:
Barcelona Endothelium Team, Barcelona, Spain
Fdn Carreras Leucemia, Barcelona, Spain
Alvarez-Larran, A:
Hosp Clin Barcelona, Inst Canc & Malalties Sang ICAMS, Hematol Dept, IDIBAPS, Barcelona, Spain
Díaz-Ricart, M:
Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Ctr Diagnost Biomed CDB,Hemostasis & Erythropathol, Barcelona, Spain
Barcelona Endothelium Team, Barcelona, Spain
|